Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis

Transplant International

Volumn 20, Issue 11, 2007, Pages 974-981

  Rayes, Nada ^a   Seehofer, Daniel ^a   Kahl, Andreas ^a   Kokott, Sophia ^a   Pratschke, Johann ^a   Frei, Ulrich ^a   Neuhaus, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cytomegalovirus; Preemptive therapy; Simultaneous pancreas kidney transplantation

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; ORTHOCLONE; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY GRAFT; KIDNEY PANCREAS TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MIDDLE AGED; PANCREAS TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 35148889792     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00526.x     Document Type: Article

References (28)

1. Lumbreras C, Fernandez I, Velosa IA, Munn SR, Paya CV. High incidence of CMV infection following pancreas transplantation. In: Michelson S, Plotkin SA, eds. Multidisciplinary Approach to Understanding Cytomegalovirus Disease. New York: Elsevier Science Publishers, 1993: 165 167.
2. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant recipients: a randomized, placebo-controlled trial. J Infect Dis 2002 185: 854.
3. Singh N, Wannstedt C, Keyes L, et al. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005 79: 1428.
4. Seehofer D, Rayes N, Neumann UP, et al. Changing impact of cytomegalovirus in liver transplantation- a single center experience of more than 1000 transplantations without ganciclovir prophylaxis. Transpl Int 2005 18: 941.
5. Ahmed J, Velarde C, Ramos M, et al. Outcome of low-dose ganciclovir for cytomegalovirus disease prophylaxis in renal-transplant recipients. Transplantation 2004 78: 1689.
6. Malaise J, Ricart MJ, Moreno A, Crespo M, Fernandez Cruz L. Cytomegalovirus infection in simultaneous pancreas kidney transplantation. Transplant Proc 2005 37: 2848.
7. Stratta RJ, Thacker LR, Sundberg AK the South Eastern Organ Procurement Foundation. Multivariate analysis of the influence of donor and recipient cytomegalovirus sero-pairing on outcomes in simultaneous kidney pancreas transplantation: the South-Eastern Organ Procurement Foundation Experience. Transplant Proc 2005 37: 1271.
8. Rayes N, Seehofer D, Schmidt CA, et al. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation 2001 72: 881.
9. Papalois VE, Hakim NS. Pancreas and Islet transplantation. In: Hakim NS, Dannovitch GM, eds. Transplantation Surgery. London: Springer, 2001: 211 213.
10. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993 44: 411.
11. Schmidt CA, Oettle H, Peng R, et al. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation. Transplantation 1995 59: 1133.
12. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002 34: 1094.
13. Kaufman DB, Leventhal JR, Gallon LG, et al. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation. Transplantation 2001 72: 1940.
14. Lo A, Stratta RJ, Egidi MF, et al. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis. Transpl Infect Dis 2001 3: 8.
15. Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002 39: 1088.
16. Axelrod D, Leventhal JR, Gallon LG, Parker MA, Kaufman DB. Reduction of CMV disease with steroid-free immunosuppression in simultaneous pancreas-kidney transplantation. Am J Transplant 2005 5: 1423.
17. Ciancio G, Burke CG, Mattiazzi A, et al. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin Transplant 2004 18: 402.
18. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analyis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005 143: 870.
19. Kalpoe JS, Schippers EF, Eling Y, Sijpkens YW, de Fijter JW, Kroes AC. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on preemptive therapy after renal and renal-pancreas transplantation. Antivir Ther 2005 10: 119.
20. Humar A, Uknis M, Carlone-Jambor C, Gruessner RW, Dunn DL, Maras A. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 1999 67: 94.
21. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000 44: 2811.
22. Keven K, Basu A, Tan HP, et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 2004 36: 3107.
23. Bechstein WO, Malaise J, Saudek F, et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. Transplantation 2004 77: 1221.
24. Gruessner AC, Sutherland DER. Pancreas transplant outcomes for United States and non-US cases as reported to the United Network for Organ Sharing and the International Pancreas Transplant Registry as of June 2004. Clin Transplant 2005 19: 433.
25. Ricart MJ, Malaise J, Moreno A, Crespo M, Fernandez-Cruz L the Euro-SPK study group. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005 20: 25.
26. Stratta RJ, Alloway RR, Lo A, Hodge EE, for the PIVOT study group. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients. Transplant Proc 2004 36: 1082.
27. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid organ transplants. Lancet 2000 356: 645.
28. Lopau K, Greser A, Wanner C. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation. Clin Transplant 2007 21: 80.